Celldex Therapeutics’ (CLDX) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a report released on Monday, Benzinga reports. The firm currently has a $67.00 price objective on the biopharmaceutical company’s stock.

Several other research analysts have also recently issued reports on the company. Wolfe Research initiated coverage on Celldex Therapeutics in a research report on Tuesday, June 11th. They issued an outperform rating and a $51.00 target price on the stock. Wells Fargo & Company upped their price objective on Celldex Therapeutics from $35.00 to $37.00 and gave the stock an equal weight rating in a report on Monday, August 12th. Stifel Nicolaus assumed coverage on Celldex Therapeutics in a report on Tuesday, June 18th. They set a buy rating and a $58.00 price objective on the stock. Finally, HC Wainwright restated a buy rating and set a $80.00 price target on shares of Celldex Therapeutics in a report on Monday, August 12th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $63.83.

Celldex Therapeutics Trading Up 1.5 %

CLDX opened at $41.85 on Monday. The stock has a fifty day simple moving average of $38.45 and a two-hundred day simple moving average of $38.78. The company has a market cap of $2.77 billion, a price-to-earnings ratio of -14.68 and a beta of 1.56. Celldex Therapeutics has a 12-month low of $22.11 and a 12-month high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.05. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. The firm had revenue of $2.50 million during the quarter, compared to the consensus estimate of $1.13 million. On average, analysts predict that Celldex Therapeutics will post -2.5 EPS for the current year.

Hedge Funds Weigh In On Celldex Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in CLDX. Point72 Asia Singapore Pte. Ltd. bought a new stake in Celldex Therapeutics during the second quarter valued at about $76,000. Headlands Technologies LLC bought a new stake in Celldex Therapeutics during the first quarter valued at about $147,000. CANADA LIFE ASSURANCE Co boosted its position in Celldex Therapeutics by 26.4% during the first quarter. CANADA LIFE ASSURANCE Co now owns 4,570 shares of the biopharmaceutical company’s stock valued at $192,000 after purchasing an additional 955 shares in the last quarter. Aigen Investment Management LP bought a new stake in Celldex Therapeutics during the fourth quarter valued at about $251,000. Finally, Ameritas Investment Partners Inc. boosted its position in Celldex Therapeutics by 34.3% during the first quarter. Ameritas Investment Partners Inc. now owns 6,198 shares of the biopharmaceutical company’s stock valued at $260,000 after purchasing an additional 1,582 shares in the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.